Table 3.
Analysis of Adverse Events
| Adverse Event | Apatinib Plus Chemotherapy [n (%)] | |
|---|---|---|
| Any Grade | Grade 3 or 4 | |
| Hematological | ||
| Leukopenia | 8 (40%) | 1 (5%) |
| Neutropenia | 6 (30%) | 1 (5%) |
| Anemia | 4 (20%) | 0 (0) |
| Thrombocytopenia | 3 (15%) | 0 (0) |
| Nonhematologic | ||
| Proteinuria | 4 (20%) | 1 (5%) |
| Hypertension | 9 (45%) | 1 (10%) |
| Hand-foot syndrome | 5 (25%) | 2 (10%) |
| Elevated transaminase | 3 (15%) | 1 (5%) |
| Hyperbilirubinemia | 2 (10%) | 0 (0) |
| Bleeding | 2 (10%) | 0 (0) |
| Fatigue | 11 (55%) | 0 (0) |
| ALP increased | 1 (5%) | 0 (0) |
| Elevated GGT | 1 (5%) | 0 (0) |
| Abdominal pain | 4 (20%) | 0 (0) |
| Decreased appetite | 6 (30%) | 0 (0) |
| Hypoproteinemia | 1 (5%) | 0 (0) |
| Diarrhea | 4 (20%) | 0 (0) |
| Elevated LDH | 1 (5%) | 0 (0) |
| Oral ulcer | 1 (5%) | 0 (0) |
| Stomatitis | 1 (5%) | 1 (5%) |
| Dysphagia | 1 (5%) | 0 (0) |
| Dysphonia | 2 (10%) | 0 (0) |
| Rash | 2 (10%) | 0 (0) |
Adverse events are listed if they were reported in at least 5% of patients in either treatment group. ALP, alkaline phosphatase; GGT, g-glutamyl transferase; LDH, lactate dehydrogenase.